557 related articles for article (PubMed ID: 9186325)
1. Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study.
Ali-el-Dein B; el-Baz M; Aly AN; Shamaa S; Ashamallah A
J Urol; 1997 Jul; 158(1):68-73; discussion 73-4. PubMed ID: 9186325
[TBL] [Abstract][Full Text] [Related]
2. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
Divrik RT; Yildirim U; Zorlu F; Ozen H
J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
[TBL] [Abstract][Full Text] [Related]
3. Early and large-dose intravesical instillation of epirubicin to prevent superficial bladder carcinoma recurrence after transurethral resection.
Mitsumori K; Tsuchiya N; Habuchi T; Li Z; Akao T; Ohyama C; Sato K; Kato T
BJU Int; 2004 Aug; 94(3):317-21. PubMed ID: 15291859
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of early intravesical instillation chemotherapy after transurethral resection of the bladder: a prospective evaluation in a consecutive series of 210 cases.
Engeler DS; Wyler S; Neyer M; Hobi C; Müller J; Schmid HP
Scand J Urol Nephrol; 2008; 42(6):522-7. PubMed ID: 18609290
[TBL] [Abstract][Full Text] [Related]
5. A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder.
Koga H; Kuroiwa K; Yamaguchi A; Osada Y; Tsuneyoshi M; Naito S
J Urol; 2004 Jan; 171(1):153-7. PubMed ID: 14665865
[TBL] [Abstract][Full Text] [Related]
6. [Intravesical instillation with epirubicin as a prophylactic treatment for superficial bladder cancer--using two different schedules].
Segawa N; Nishida T; Takahara K; Nomi H; Azuma H; Katsuoka Y
Hinyokika Kiyo; 2008 Nov; 54(11):711-6. PubMed ID: 19068724
[TBL] [Abstract][Full Text] [Related]
7. [Continuous intravesical instillation of epirubicin immediately after transurethral resection of superficial bladder cancer: a prospective controlled study].
Maekawa S; Suzuki H; Ohkubo K; Aoki Y; Okada T; Maeda H; Ogura K; Arai Y
Hinyokika Kiyo; 2000 May; 46(5):301-6. PubMed ID: 10876750
[TBL] [Abstract][Full Text] [Related]
8. Effect of intravesical instillation on performance of uCYT+ test.
Lodde M; Mian C; Negri G; Vittadello F; Comploj E; Palermo S; Staffler A; Brössner C; Pycha A
Urology; 2004 May; 63(5):878-81. PubMed ID: 15134970
[TBL] [Abstract][Full Text] [Related]
9. [Intravesical instillation of epirubicin in the prophylactic treatment of recurrent superficial bladder cancer].
Kobayashi M; Sugaya Y; Yuzawa M; Morita T; Kobayashi Y; Tokue A
Hinyokika Kiyo; 1998 Dec; 44(12):861-4. PubMed ID: 10028430
[TBL] [Abstract][Full Text] [Related]
10. [Intravesical instillation of doxorubicin or epirubicin for chemoprophylaxis of superficial bladder cancer--the fifth study of the Japanese Urological Cancer Research Group for Adriamycin/Farumorubicin].
Hinotsu S; Akaza H; Isaka S; Kagawa S; Koiso K; Kotake T; Machida T; Matsumura Y; Niijima T; Obata K; Ohashi Y; Ohe H; Shimazaki J; Tashiro K;
Gan To Kagaku Ryoho; 2002 Jan; 29(1):73-80. PubMed ID: 11816482
[TBL] [Abstract][Full Text] [Related]
11. Randomized study of single instillation of epirubicin for superficial bladder carcinoma: long-term clinical outcomes.
Liu B; Wang Z; Chen B; Yu J; Zhang P; Ding Q; Zhang Y
Cancer Invest; 2006 Mar; 24(2):160-3. PubMed ID: 16537185
[TBL] [Abstract][Full Text] [Related]
12. [A randomized study on intravesical pirarubicin (THP) chemoprophylaxis of recurrence after transurethral resection of superficial bladder cancer].
Miki T; Nonomura N; Kojima Y; Okuyama A; Nakano E; Kiyohara H; Fujioka H; Koide T; Wakatsuki A; Kuroda H; Sugao H; Seguti T; Takeyama M; Yamaguchi S
Hinyokika Kiyo; 1997 Dec; 43(12):907-12. PubMed ID: 9488944
[TBL] [Abstract][Full Text] [Related]
13. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy.
Tzai TS; Chow NH; Lin JS; Yang WH; Tong YC
Anticancer Res; 1998; 18(6B):4717-21. PubMed ID: 9891547
[TBL] [Abstract][Full Text] [Related]
14. Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer.
Hendricksen K; Witjes WP; Idema JG; Kums JJ; van Vierssen Trip OB; de Bruin MJ; Vergunst H; Caris CT; Janzing-Pastors MH; Witjes JA
Eur Urol; 2008 May; 53(5):984-91. PubMed ID: 18248876
[TBL] [Abstract][Full Text] [Related]
15. Sequential bacillus Calmette-Guerin and epirubicin versus bacillus Calmette-Guerin alone for superficial bladder tumors: a randomized prospective study.
Ali-El-Dein B; Nabeeh A; Ismail EH; Ghoneim MA
J Urol; 1999 Aug; 162(2):339-42. PubMed ID: 10411034
[TBL] [Abstract][Full Text] [Related]
16. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of a randomized trial with epirubicin comparing short-term versus long-term maintenance treatment.
Nomata K; Noguchi M; Kanetake H; Tsuda N; Hayashi M; Yamashita S; Sakuragi T; Kusaba Y; Shindo K;
Cancer Chemother Pharmacol; 2002 Oct; 50(4):266-70. PubMed ID: 12357299
[TBL] [Abstract][Full Text] [Related]
17. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study.
Gudjónsson S; Adell L; Merdasa F; Olsson R; Larsson B; Davidsson T; Richthoff J; Hagberg G; Grabe M; Bendahl PO; Månsson W; Liedberg F
Eur Urol; 2009 Apr; 55(4):773-80. PubMed ID: 19153001
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy and safety of different dosages of intravesical epirubicin instillation for prevention of primary superficial bladder carcinoma from recurrence].
Wu ZB; Lin GB; Chen BJ; Wu ZM; Rong RM
Zhonghua Zhong Liu Za Zhi; 2005 Aug; 27(8):507-9. PubMed ID: 16188156
[TBL] [Abstract][Full Text] [Related]
19. Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study.
Cai T; Nesi G; Tinacci G; Zini E; Mondaini N; Boddi V; Mazzoli S; Bartoletti R
J Urol; 2008 Jul; 180(1):110-5. PubMed ID: 18485394
[TBL] [Abstract][Full Text] [Related]
20. A 1-year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk non-muscle-invasive bladder cancer.
Serretta V; Morgia G; Altieri V; Di Lallo A; Ruggiero G; Salzano L; Battaglia M; Falsaperla M; Zito A; Sblendorio D; Melloni D; Allegro R;
BJU Int; 2010 Jul; 106(2):212-7. PubMed ID: 20070299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
